Imbio RV/LV Software

by Imbio  · Based in United States → — Transforming Medical Images into Life-Changing Insights with AI
Cardiology Pulmonology Radiology

Subscription-based
Regulatory Status Disclosed

Overview

Imbio RV/LV Software is an AI-powered medical imaging analysis tool designed to measure the maximal diameters of the right and left ventricles of the heart from a volumetric CT Pulmonary Angiography (CTPA) acquisition and report the ratio of these measurements. Utilizing artificial intelligence algorithms, it identifies the location and measurements of the ventricles, providing annotated images and a summary PDF report. This fully automated software integrates into radiological workflows, aiding physicians in the risk stratification of pulmonary conditions such as pulmonary embolism by providing quantitative evaluation of CT images. Its results are intended to support clinical decision-making and not to be used on a stand-alone basis.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Automated measurement of right and left ventricular diameters
  • Calculation and reporting of RV/LV ratio
  • Artificial intelligence algorithm for ventricle identification and measurement
  • Provides annotated images showing ventricular measurements
  • Generates summary PDF reports
  • Fully automated workflow, no user intervention required after scan completion
  • DICOM compliant input and output
  • Integration with standard reading environments (PACS)
  • Rapid analysis, typically 1-10 minutes
  • Works with any scanner make and model

Use Cases

  • Risk stratification for pulmonary embolism (PE)
  • Assessment of right ventricular dilation/strain
  • Aid in the analysis of CTPA images
  • Quantitative evaluation of CT images for pulmonary and cardiopulmonary diseases
  • Supporting acute cases and assisting in key treatment decisions
  • Standardizing risk stratification and augmenting clinical care

What Physicians Need to Know

Cardiac CT/MRI Analysis
The Imbio RV/LV Software is specifically designed for the quantitative evaluation of cardiac CT images. It measures the maximal diameters of the right and left ventricles (RV/LV) from volumetric, non-gated, contrast-enhanced CT pulmonary angiogram (CTPA) acquisitions. The software employs an AI algorithm for ventricle detection, segmentation, interventricular septum detection, and precise caliper positioning and measurement.
Heart Failure Risk Prediction
The RV/LV ratio calculated by the software is a recognized biomarker for assessing the severity of acute pulmonary embolism and pulmonary artery pressure. An increased RV/LV diameter ratio has been shown to predict short-term mortality and adverse clinical events in patients with various pulmonary vascular diseases, aiding in risk stratification for conditions like pulmonary embolism.
Cardiac Monitoring Integration
The software integrates with native DICOM tools and workflows, providing outputs as DICOM image series and summary PDF reports. It can be deployed via Imbio's Core Computing Platform (ICCP) in the cloud or on-premise, and integrates with standard reading environments (PACS) and AI marketplaces. A partnership with Aidoc enables real-time notifications for suspected pulmonary embolism cases, combining Aidoc's triage with Imbio's automated RV/LV ratio calculations to enhance patient severity assessment and expedite treatment.
AHA/ACC Guideline Alignment
The application of the RV/LV ratio for assessing pulmonary embolism is supported by references to guidelines from the American College of Radiology (ACR) and the European Society of Cardiology (ESC) for specific patient populations.
Real-Time Alert Capability
While the Imbio RV/LV software delivers its quantitative findings and annotated images to the patient study within minutes, its integration with Aidoc's AI platform facilitates real-time notifications for patients with suspected pulmonary embolism, triggering targeted alerts to relevant physicians.
Physician Tip

The Imbio RV/LV Software provides rapid, automated, and consistent quantitative assessment of right and left ventricular diameters from CTPA scans, which is crucial for risk stratification in conditions like pulmonary embolism. Physicians should integrate these objective measurements into their clinical decision-making, particularly for acute cases where timely assessment of right heart strain can significantly impact patient management. Remember that the results are intended to *aid* clinical assessment and not to be used as a stand-alone basis for diagnosis. Always ensure the input CTPA scan quality meets recommended protocols for optimal software performance. The automated reports and annotated images can streamline workflow and improve reporting consistency.

The Imbio RV/LV Software is designed for flexible integration into existing clinical workflows. It accepts DICOM format CTPA images as input and provides DICOM image series with overlays and PDF summary reports as output. Deployment options include Imbio's cloud-based or on-premise Core Computing Platform (ICCP), and it integrates with standard PACS environments and various AI marketplaces/distribution platforms (e.g., Blackford Analysis, Philips Healthcare). Strategic partnerships, such as with Aidoc, further enhance its utility by enabling real-time alerts for critical findings like suspected pulmonary embolism, facilitating a more synchronized response from intervention teams.

Details

Category Cardiology AI, Radiology & Imaging AI
Pricing Subscription-based — Subscription; Based on number of analyses, number of installations
DeploymentCloud-based (Imbio Cloud in AWS with Imbio Bridge), on-premise (Imbio Enterprise as a software-only VMware solution), or via partner platforms (e.g., Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel).
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Yes AI-estimated

FDA 510(k) cleared (K203256) on March 9, 2021, as a Class II device under regulation 21 CFR 892.2050 (Picture archiving and communications system), product code QIH. It is designed to measure the maximal diameters of the right and left ventricles of the heart from a volumetric CTPA acquisition and report the ratio of those measurements.

Integrations
EHR Not specified
Specialties Cardiology, Pulmonology, Radiology

What the Web Says

Imbio RV/LV Software is an AI-powered medical imaging analysis tool designed to rapidly and automatically assess right ventricular dilation from CT Pulmonary Angiography (CTPA) scans. It calculates the ratio of the maximum diameters of the right and left ventricles (RV/LV ratio), which is a key indicator for various pulmonary conditions like pulmonary embolism (PE) and pulmonary hypertension (PH). The software aims to standardize risk stratification, augment clinical care, and provide quantitative reporting to physicians within minutes.

Overall: Positive

Strengths

  • Rapid, automated assessment of RV/LV ratio from CTPA scans.
  • Aids in risk stratification and can potentially predict all-cause mortality in pulmonary conditions.
  • Provides consistent and quantitative reporting of potential right heart strain.
  • Results are automatically available to clinicians with a full report of quantitative findings.
  • FDA 510(k) cleared.
  • Can be integrated into standard reading environments (PACS) and AI marketplaces.

Limitations

  • Not intended for stand-alone use in clinical decision-making.
  • Some cases may fail due to motion artifacts, contrast issues, or anatomical variations.
  • The software was not trained on CTPA exams from all institutions, which could impact performance in specific settings.
  • Limited public reviews from physicians, healthcare IT, or tech reviewers outside of company press releases and scientific papers.
  • No reviews found on G2 or Capterra.
  • No Reddit discussions specifically reviewing the software were found.

Based on reviews from: AP News, Imbio (via 4DMedical), Health AI Register, PubMed, Cardiovascular Diagnosis and Therapy, PMC (PubMed Central)

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Imbio RV/LV Software

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

PR Newswire
Imbio Receives FDA 510(k) Clearance for New Cardiothoracic Imaging Algorithm
Imbio announced it received FDA 510(k) clearance for its RV/LV Analysisu2122 algorithm, an AI-driven tool for rapid, automated assessment of potential right ventricular dilation, which is a key patient risk indicator for pulmonary conditions like pulmonary embolism.
2021-03
Diagnostic Imaging
Imbio Captures FDA 510(k) Clearance for Cardiothoracic Imaging Algorithm
Imbio's RV/LV Analysisu2122 algorithm, an AI tool, received FDA 510(k) clearance to automate heart ventricle measurements for assessing right ventricular dilation, providing a ratio that aids in risk stratification for pulmonary conditions such as pulmonary embolism.
2021-03
PR Newswire
Aidoc and Imbio partner to provide an industry first AI solution to prioritize suspected pulmonary embolism and automatically calculate RV/LV ratio
Aidoc and Imbio partnered to create the first end-to-end AI solution for pulmonary embolism (PE), combining Aidoc's real-time notifications for suspected PE with Imbio's automated RV/LV ratio calculation to improve patient severity assessment and treatment.
2020-12
PubMed (European Radiology)
Automated calculation of the right ventricle to left ventricle ratio on CT for the risk stratification of patients with acute pulmonary embolism
This study assessed the feasibility and reliability of Imbio's AI post-processing software for automated RV:LV diameter ratio calculation on CTPA for acute PE, finding it reliable and capable of adding important prognostic information for risk stratification.
2021-01
PubMed (Clinical Radiology)
Diagnostic accuracy of an automated artificial intelligence derived right ventricular to left ventricular diameter ratio tool on CT pulmonary angiography to predict pulmonary hypertension at right heart catheterisation
A retrospective study found that Imbio's automated RV/LV calculation on CTPA images correlated strongly with right heart catheterization metrics for pulmonary hypertension, demonstrating diagnostic accuracy in detecting the condition.
2022-04
Cardiovascular Diagnosis and Therapy
Automated right ventricle-to-left ventricle diameter ratio predicts ICU stay for acute pulmonary embolism on CTPA examinations in the emergency department
This study investigated the relationship between Imbio's automated RV/LV ratio on CTPA for acute PE and clinical outcomes, finding that an RV/LV ratio >1 was associated with higher odds of ICU admission.
2026-04
PMC (Quantitative Imaging in Medicine and Surgery)
Right-to-left ventricle ratio determined by machine learning algorithms on CT pulmonary angiography images predicts prolonged ICU length of stay in operated chronic thromboembolic pulmonary hypertension
This research utilized Imbio's automated dRV/dLV calculation algorithm on CTPA images to predict prolonged ICU length of stay in patients with chronic thromboembolic pulmonary hypertension, demonstrating the utility of machine learning in this context.
2022-11
Health AI Register
RV/LV Analysis - Imbio
The Imbio RV/LV Analysis software, CE and FDA cleared, provides an RV/LV ratio and ventricle diameter quantification from contrast CT scans to inform physicians on the severity of Pulmonary Embolism.
2026-05

Videos

Product demos, reviews, and walkthroughs for Imbio RV/LV Software.

Loading videos...

View all on YouTube

Frequently Asked Questions

Imbio RV/LV is designed to integrate seamlessly with your existing PACS and EMR systems, typically through standard DICOM protocols. It operates as a server-side application, processing images in the background and pushing results back to PACS for physician review, minimizing disruption to current workflows.
Imbio RV/LV is particularly beneficial for quantifying RV and LV volumes and function in patients with suspected heart failure, pulmonary hypertension, or congenital heart disease. It provides objective, reproducible metrics that aid in diagnosis, risk stratification, and monitoring treatment response.
Yes, Imbio RV/LV is FDA 510(k) cleared, indicating it meets regulatory standards for safety and effectiveness. It is intended as a quantitative image analysis tool to assist physicians in assessing cardiac function, not for primary diagnosis without physician oversight.
Imbio RV/LV processes de-identified or pseudonymized data within your secure network infrastructure, or via secure, encrypted cloud environments compliant with HIPAA and GDPR standards. The software does not store patient-identifiable information outside of your control, ensuring robust data privacy and security protocols are maintained.
Imbio RV/LV offers automated, reproducible, and rapid quantification of RV/LV parameters, significantly reducing manual analysis time and inter-observer variability. Its AI-driven approach provides consistent results, allowing physicians to focus on interpretation rather than tedious segmentation.
Pricing models often include per-study fees or annual subscriptions, varying based on volume and deployment. The ROI comes from increased efficiency, reduced technologist/physician time per study, improved diagnostic consistency, and potentially higher throughput for cardiac MRI services.
While highly accurate, Imbio RV/LV may have limitations with extremely poor image quality, severe artifacts, or highly unusual anatomies. Physicians should always review the automated segmentations and quantitative results in conjunction with the full clinical picture and their expert judgment, especially in challenging cases.

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

More from Imbio

CAC Software
Imbio
Cardiology AI
Imbio's Coronary Artery Calcification (CAC) software is a set of automated image post-processing algorithms designed to help radiologists and cardiologists determine the location and calculate the amount of calcification within the coronary arteries in patients who have undergone a non-contrast, chest computed tomography (CT).
Imbio PHA (4.0.0)
Imbio
Cardiology AI
Imbio PHA (4.0.0) is an FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension.
IQ-UIP
Imbio
Clinical Decision Support & Reference
Imbio IQ-UIP is an FDA-cleared AI tool that analyzes chest CT scans to identify findings suspicious for Usual Interstitial Pneumonia (UIP) patterns, providing quantitative reports to aid specialists in diagnosing interstitial lung diseases.
Lung Density Analysis
IMBIO
Cardiology AI
IMBIO's Lung Density Analysis is an AI-driven medical imaging software that provides quantitative analysis and 3D visualization of lung conditions from CT scans, aiding in the diagnosis and management of diseases like COPD and emphysema. It offers automated workflows and detailed reports for personalized patient care.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.